2025年1月1日 · What is lonafarnib? Lonafarnib is for use in people with certain rare genetic conditions that cause premature and rapid aging. Lonafarnib is for use in adults and children at least 12 months old whose bodies have reached a certain size (a body surface area of 0.39 square meters).

2020年11月23日 · Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain...

WHAT IS ZOKINVY ® (lonafarnib)? ZOKINVY (zoh-KIN-vee) is a prescription medicine used to treat Hutchinson-Gilford Progeria Syndrome and some types of Progeroid Laminopathies known as processing-deficient Progeroid Laminopathies.

Lonafarnib is in a class of medications called farnesyltransferase inhibitors. It works by preventing proteins from building up and damaging cells. How should this medicine be used? Lonafarnib comes as a capsule to take by mouth. It is usually taken with food twice a day in the morning and evening with meals.

Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies.

Find patient medical information for lonafarnib oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Lonafarnib is used to help reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). HGPS is a genetic condition in which patients have a noticeable, rapid appearance of aging beginning in childhood.

2024年4月9日 · Zokinvy (lonafarnib) is a farnesyltransferase inhibitor indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome; and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like pro...

2024年4月4日 · ZOKINVY (lonafarnib) is a farnesyltransferase inhibitor. The chemical name for lonafarnib is 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H- benzo[1,2] cyclohepta [2,4-b]pyridin-11-yl]piperidin-1-yl]-2- oxoethyl]piperidine-1-carboxamide.

2024年1月30日 · Zokinvy (lonafarnib) is used for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria). Includes Zokinvy side effects, interactions and indications.